Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9615 posts found.

amgen_hq

Amgen’s Prolia achieves positive top-line Phase III results after 12 months

August 30, 2016 Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III

Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …
News
clinical_trial-web

Sanofi & Regeneron’s Praluent cholesterol treatment smashes Phase III target

August 30, 2016 Manufacturing and Production, Research and Development Regeneron, Sanofi, apheresis, cholesterol, phase III

Sanofi and Regeneron have announced that their Praluent injection generated positive Phase III results investigating patients with an inherited form …
News
asthma_inhalers

Vectura asthma treatment fails at Phase III

August 30, 2016 Manufacturing and Production, Research and Development asthma, inhaler, phase III, phase III failure, vectura

Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted …
News
top_ten

Top ten stories in the pharmaceutical industry this week

August 26, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharmafile, top 10

If this week left you feeling with a sense of déjà vu, you could certainly be forgiven. With US politicians …
News
mylan_building

Mylan announces immediate plans to cut price of EpiPen

August 25, 2016 Medical Communications, Research and Development Mylan, clinton, epipen, increase

Subject to intense pressure over the last few days, Mylan has made an attempt to avoid becoming “another Valeant” by …
News
chemo-web

Boost for Clovis as FDA grants priority review for rucaparib in ovarian cancer

August 25, 2016 Research and Development, Sales and Marketing FDA, clovis, ovarian cancer, rucaparib

Clovis Oncology has announced that the US Food and Drug Administration has accepted its new drug application for rucaparib, and …
News
novartis_malaria_researcher

Positive Phase III results for Novartis MS drug

August 25, 2016 Research and Development Novartis, multiple sclerosis, phase III

Novartis has announced positive Phase III results for its EXPAND study, an evaluation of the efficacy and safety of orally-administered, …
News
teva_copy

Teva loses patent protection on lucrative MS treatment

August 25, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis

Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …
News
amgen_flag

FDA says no to Amgen’s Parsabiv

August 25, 2016 Research and Development, Sales and Marketing Amgen, FDA, par

Amgen has announced that the US Food and Drug Administration (FDA) has issued a complete response letter rejecting Parsabiv (etelcalcetide) …
News
fdaoutsideweb

Medical device user fees to increase 68% for 2018 to 2022

August 25, 2016 Research and Development, Sales and Marketing FDA, Medical device

The Food and Drug Administration has reached an agreement with the medical device industry and laboratory community on proposed recommendations …
News
mylan_plus_hero_720x510

Mylan latest target of US anger on drug pricing with EpiPen price increase

August 24, 2016 Research and Development, Sales and Marketing Mylan, US, congress, controversy, epipen, price gouging, price increase

The US congress is again subjecting the pharmaceutical industry to heavy scrutiny over drug pricing policies with Mylan its latest …
News

NICE approves lung cancer and leukaemia treatments

August 24, 2016 Research and Development, Sales and Marketing Alimta, CDF, NICE, bosulif, bosutinib, pemetrexed

The National Institute for Health and Care Excellence (NICE) has issued its approval of two drugs for routine use on …
News
pfizer_sky

Pfizer to acquire AstraZeneca’s anti-infective business for $550 million upfront

August 24, 2016 Research and Development, Sales and Marketing AstraZeneca, Pfizer, Zavicefta, anti-infective

Pfizer has announced that it is to acquire AstraZeneca’s small molecule anti-infective business in a deal potentially worth up to …
News
eylea-product-box-md

NICE recommends Eylea as first-line treatment for sight threatening condition

August 24, 2016 Research and Development, Sales and Marketing Bayer, Eylea, NHS, NICE, first-line treatment

Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Eylea (aflibercept) as a cost-effective …
News
1397501171305

AbbVie’s leukaemia drug granted positive opinion by MHRA through EAMS

August 23, 2016 Research and Development, Sales and Marketing

AbbVie’s investigational treatment for chronic lymphocytic leukaemia (CLL) venetoclax has been granted a positive scientific opinion by the Medicines and …
News
The Gateway to Local Adoption Series

Latest content

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026

Study explores speech as marker in rare neurodegenerative disease

April 27, 2026

Ofichem brings all brands under single trading name

April 23, 2026